Tag: big pharma

FDA Removing Pharmaceutical Representatives From Advisory Panels

The Food and Drug Administration (FDA) is removing pharmaceutical company representatives from advisory committees in a bid to limit industry influence.

Dr. Marty Makary, the FDA’s new commissioner, issued a directive that eliminates the role of pharmaceutical representative

“Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official members of FDA advisory committee members represents a cozy relationship that is concerning to many Americans,” Makary said in a statement on April 17. “In fact, the FDA has a history of being influenced unduly by corporate interests.”

The FDA has 32 different advisory committees, including panels that advise the agency on vaccines, food, and medical devices. Members are primarily a mix of federal employees and experts who do not work for industries.

But each FDA committee has an industry representative and an alternate industry representative. The Vaccine and Related Biological Products Advisory Committee, for instance, had a Pfizer officer and a Dynavax officer listed on the roster for its most recent meeting.

The industry representatives do not vote on what advice to convey to the FDA, but “offer perspective of a pharmaceutical company,” Kim Witczak, who has served on several FDA advisory committees, told The Epoch Times in an email.

“Sometimes they will say something that could influence or sway the discussion. I always wondered why they were on the committee,” she said.

Keep reading

Mental Health “Experts” FEAR Secretary Kennedy’s Investigation into Psychiatric Drugging

Within a few weeks of Donald Trump’s inauguration, the President signed an Executive Order establishing the Make America Healthy Again Commission (MAHA), which, among other things, will be “assessing the prevalence of and threat posed by the prescription of Selective Serotonin Reuptake Inhibitors (SSRIs), antipsychotics, mood stabilizers, stimulants and weight-loss drugs.” In other words, officialdom finally is looking at the out-of-control unscientific chemical experimentation used to address unwanted behaviors.

Alert the media! Get Megyn Kelly on the phone! Finally, a governmental body will be looking into the serious risks associated with prescription mind-altering drugs. It’s decades in the making. But, as they say, “better late than never.” It was no surprise then that within a month of that announcement the mental health industry was none too pleased and released a “joint statement” about the wonders of its mind-altering chemical elixirs.

According to the statement, “these drugs provide relief for many young people enabling them to participate fully in treatment, school, social activities, and family life — all key aspects of healthy development.” Utter nonsense.

“Healthy development?” There is no such thing as the decades-long touted “chemical imbalance.” That theory finally got debunked in 2022 research published by Professor Joanna Moncrieff and Dr. Mark Horowitz. So, since it’s clear that people are not “short” on certain brain chemicals as a reason for depression, then why are those chemicals being prescribed as “treatment?” And, make no mistake, lots and lots of Americans are being drugged.

According to data gathered in 2020 by IQVIA (Formerly IMS Health) and made public by the Citizens Commission on Human Rights (CCHR) in January of 2021, nearly 77 million Americans are taking at least one prescription psychiatric drug. The breakdown of who is drugged is jaw dropping crazy. There were more than 85 thousand 0–1-year-olds, nearly 140,000 2–3-year-olds, 215,000 4- to five-year-olds, two-and-a-half million 6–12-year-olds and more than three million 13–17-year-olds taking psychiatric mind-altering drugs every day.

Keep reading

Fired FDA Chief Is Now Out Trashing RFK Jr. and his Autism Study on the Fake News – Big Pharma Has Most to Lose

Dr. Peter Marks, the FDA’s top vaccine official and a key figure in the first Trump administration’s Operation Warp Speed, was ousted from his post earlier this month.

​Dr. Peter Marks is an American hematologist-oncologist who has served as the director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) since 2016.

As CBER director, Marks was responsible for reviewing and providing advice during product development, evaluating applications, and making approval decisions based on safety and effectiveness data.

He oversaw the FDA’s vaccine programs and played a pivotal part in the rapid development and approval of the experimental COVID-19 vaccines under Operation Warp Speed during President Donald Trump’s first term.

Sources close to the matter told the Wall Street Journal that Marks submitted his resignation on Friday after a blunt ultimatum from a Health and Human Services (HHS) official: step down voluntarily or face termination.

His exit, effective April 5, marks yet another victory for HHS Secretary Robert F. Kennedy Jr.’s aggressive push to purge the federal health apparatus of what he calls entrenched bureaucrats peddling “misinformation and lies.”

It was very telling that Big Pharma stocks plunged following his resignation.

Shares of vaccine makers Moderna and Novavax, along with several other biotech companies, plunged following his resignation.

Now, Marks is out hitting the Sunday shows and attacking Robert Kennedy Jr.  It makes you wonder who is behind this?

The Disgraced former FDA official is ALREADY defending Big Pharma from RFK Jr’s groundbreaking study on autism.

This is how committed the Big Money players are with keeping the vaccines flowing no matter how many Americans will be injured or killed.

Keep reading

Trump Admin Launches National Security Probe Into Pharma, Semiconductor Imports

The Trump administration has launched an investigation into the effects on national security of importing semiconductors and pharmaceutical products, according to Federal Register filings on Monday.

The Commerce Department, in a pair of Federal Register notices set to be published on April 16, said that the probes were initiated under Section 232 of the Trade Expansion Act—which allows the president to impose tariffs on imports considered a threat to national security.

The department stated that it began investigating the national security implications of importing semiconductors and semiconductor manufacturing equipment (SME) on April 1.

This includes “semiconductor substrates and bare wafers, legacy chips, leading-edge chips, microelectronics, and SME components,” as well as derivative products of those items, according to one of the filings.

The probe will assess current and projected demand for semiconductors and SME in the United States; the extent to which domestic production can or is expected to meet that demand; the role of foreign fabrication and assembly; the concentration of U.S. semiconductor imports; and the potential for export restrictions by other nations; among other issues.

In another notice, the department said it was investigating imports of pharmaceuticals and their ingredients. This includes “finished generic and non-generic drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients and key starting materials, and derivative products of those items.”

Keep reading

FDA Says It Plans to Phase out Animal Testing for Drug Development

The Food and Drug Administration (FDA) on April 10 said it will be phasing out animal testing for monoclonal antibodies and other drugs.

FDA officials said that its animal testing requirement will be “reduced, refined, or potentially replaced” with other approaches, including advanced computer simulations utilizing artificial intelligence and lab-grown products that are designed to mimic human organs.

The agency will also start looking at preexisting, real-world safety data from other countries that have regulatory standards similar to those in the United States.

“For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,” FDA Commissioner Dr. Marty Makary said in a statement.

He said that the move “represents a major step toward ending the use of laboratory animals in drug testing.”

Companies that submit what the agency described as strong safety data from non-animal testing could receive faster review, according to the FDA.

Keep reading

Swiss Pharma Company Announces $23 Billion U.S. Investment Days After Trump Pledged ‘Major Tariff’ on Drug Imports

Pharmaceutical company Novartis announced plans to build seven facilities in the United States and expand others in a $23 billion investment over five years on the heels of President Donald Trump’s announcement of forthcoming tariffs on imported drugs.

The Swiss company revealed the major investment in a press release.

“This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs,” the release said.

Six of the facilities will be manufacturing plants, two of which will focus on radioligand therapy in Florida and Texas. It remains to be seen where the other four plants will be built.

Moreover, the company is establishing a biomedical research innovation center in San Diego as part of the investment, and it is expanding three of its production facilities in Indiana, New Jersey, and California.

The company also noted that its goal is to ensure “all key Novartis medicines for US patients will be made in the United States.”

Keep reading

Profits Over Patients: How Big Pharma Weaves Its Web Of Corruption And Drug Dependency

 I never set out to be an advocate. I wasn’t a doctor, scientist, or policy expert. I was just a regular person who, like so many, blindly trusted that our healthcare system was designed to protect us.

But life has a way of pulling us into the arena when we least expect it.

After the tragic and unexpected loss of my husband Woody to the antidepressant Zoloft he was prescribed for insomnia, I was thrust into a world I never imagined—one where medicine wasn’t solely about healing, but deeply entangled in a system that prioritizes profit over safety, buries harms, and keeps the public in the dark.

For over two decades, I’ve had a front-row seat to how this system truly operates—not the illusion of rigorous oversight we see in medical journals or glossy pharmaceutical ads, but the reality of how industry influence is woven into every stage.

I’ve met with regulators, testified before the FDA and Congress, filed a wrongful death and failure-to-warn lawsuit against Pfizer, and earned a seat on the FDA’s Psychopharmacologic Drugs Advisory Committee as a consumer representative.

I’ve also spoken at and participated in global conferences like Selling Sickness, Too Much Medicine, and the Harms in Medicine meeting in Erice, Italy—where some of the world’s leading experts acknowledge what few in mainstream medicine dare to say:

Our healthcare system isn’t about health—it’s about business.

And in this business, harm isn’t an accident. It’s built into the system.

The more I uncovered, the more I realized:

We aren’t just patients. We are customers.

And we are all trapped in Big Pharma’s spiderweb of influence.

Keep reading

The Media Playbook for Measles Looks a Lot Like Its COVID Playbook — This Time, Kids Are the Pawns

There are moments in the history of a movement that test its resolve. For the medical freedom movement, this is one of those moments.

We are in the midst of another full-on attack by the pharmaceutical-industrial complex, aided and abetted by a beholden mainstream media united around its allegiance to a $69 billion vaccine industry.

Five years ago, we fought back as our government, Big Media and Big Pharma orchestrated and executed a COVID-19 fear campaign — a campaign built on lies, deception and censorship — and then parlayed the public’s fear into dangerous and deadly medical mandates and hospital protocols that continue to cause profound harm.

The upside to COVID-19 global disaster?

It opened the eyes of millions more people to the dangers of shoddily tested vaccines, regulatory agency hubris and one-size-fits-all “medicine.”

As our movement has grown exponentially, so has our threat to Big Pharma.

In response, we’re seeing the same tactics rolled out again. This time, it’s measles. This time, children are the pawns in pharma’s playbook.

Children’s Health Defense (CHD) stood strong and stayed true to our mission during COVID. We’re standing just as strong now. We remain just as committed now to the truth, informed consent and medical freedom as we were during the pandemic.

As pharma ramps up its measles playbook, our No. 1 job is to dismantle the vaccine industry’s lies — broadcast far and wide through the industry’s most reliable and faithful megaphone: mainstream media.

The media would have you believe that measles is a “deadly” disease. But any suggestion that MMR (measles-mumps-rubella) vaccines are safer than measles infection isn’t supported by facts.

In fact, between 2000 and 2024, nine measles-related deaths were reported to the CDC. During the same period, 141 deaths following MMR or MMRV vaccination were reported in the U.S. to the Vaccine Adverse Event Reporting System (VAERS) — suggesting the MMR vaccine can be deadlier than measles.

The media echo the same familiar refrain: The MMR vaccine is “overwhelmingly safe.”

In fact, the MMR vaccine is associated with serious health risks. The package insert for Merck’s MMRII says, “M-M-R II vaccine has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.”

Research also shows the MMR vaccine causes febrile seizures, anaphylaxis, meningitis, encephalitis, thrombocytopenia, arthralgia and vasculitis. In 2004, researchers at the Centers for Disease Control and Prevention found that boys vaccinated with their first MMR vaccine on time were 67% more likely to be diagnosed with autism compared to boys who got their first vaccine after their 3rd birthday.

The media insist there’s no viable treatment for measles — hence prevention, with the MMR vaccine, is the sole solution.

In fact, as CHD reported, doctors in West Texas are successfully treating measles with budesonide and vitamin A. Even the World Health Organization recommends vitamin A.

Yet some hospitals and doctors are refusing to treat measles patients with budesonide. Texas health officials rejected pleas by a treating physician to endorse the treatment and get the word out to hospitals about its effectiveness.

Sound familiar?

Keep reading

Who Needs Vaccine Data When You Have Vaccine Mandates?

FDA Gene-Editing mRNA Vaccine Chief – Peter Marks – has always been a strong proponent of vaccine mandates. Marks also has as a history of overruling large expert panels for FDA approval of gene therapies at the agency.

STAT News reported that “Marks was one of the architects of Operation Warp Speed, the $18 billion U.S. effort to speed development of Covid-19 vaccines. He regularly embraced regulatory flexibility. And he spoke not infrequently about the importance of accelerated approval for next-generation treatments, including with those whose potential benefits weren’t always crystal-clear in clinical trial data.”

“Vaccine Mandates Are Not Going to Get Us THERE. It’s Got to Be Compelling Evidence.” – Vaccine Chief Peter Marks

During a 4-hour Public Health Workshop hosted by Duke University on March 20, 2025, Marks alluded to having contentious disputes with the higher-ups of the new Health & Human Services (HHS) administration (aka – Secretary Kennedy) over ‘the need for vaccine efficacy and vaccine safety data’ when FDA-approved vaccines can just be mandated.

“How We Generate Evidence Going Forward”

Throughout the 4-hour workshop, Marks and his colleagues strategically avoided discussing retrospective data analyses (i.e. analyzing the adverse events of vaccines in the US government databases) and the specifics on how to measure safety data going forward.

“By Definition, Vaccines Are Very Safe Medical Products”

“By definition, when we are developing vaccines for broad use, one of their direct benefits has to be that they are very safe medical products. That just goes without saying, because that goes to getting acceptance for the individual’s direct benefit.”

Keep reading

Following the Money on RFK’s Top Targets, Pharma Ads & Soda

What do Big Pharma ads on TV and Diet Coke have in common? Both are targets of Robert F. Kennedy, Jr., the new head of the Health and Human Services department.

In his early efforts to press the “Make America Healthy Again,” Kennedy has singled out two seemingly different issues: those ubiquitous television ads for pharmaceuticals, and whether people on federal food assistance programs should be able to buy soda and junk food on the taxpayer dime.

Popping open a can of Diet Coke to open the latest episode of The Drill Down, host Peter Schweizer savors the taste of crony capitalism.

Robert F. Kennedy Jr.’s campaign to swiftly bar the use of food stamps to buy soda is fueling tensions between his team and the Agriculture Department. Of course, the American Beverage Association, a trade group that lobbies on behalf of “Big Soda,” is firing back, too.

HHS wants the Trump administration to approve petitions from the governors of Kentucky and West Virginia to ban soda purchases from the Supplemental Nutrition Assistance (SNAP) program for the first time. But the USDA controls the program, not HHS. So that sets up a conflict, and for the beverage industry the stakes are very high.

The SNAP program costs $100 billion per year and serves about 42 million Americans.

Co-host Eric Eggers says that Coca-Cola would see a 2.5 percent decline in worldwide sales if sugary sodas were no longer covered by SNAP nationwide. Coca-Cola is just one of many makers of soda. Moreover, about 25 percent of all SNAP program spending is done at the cash registers at Walmart, so its influence will be felt as well.

The show also takes on another perennial issue and MAHA target — pharmaceutical advertising on television.

Every American is used to hearing and seeing ads for miracle drugs when watching television, especially news programs and sports. They often show bright, happy old people whirling around in golf carts or briskly walking while a voiceover speed-reads a cocktail of terrifying potential side effects.

“I’m generally a free-speech guy, but what is the purpose of these ads? They are meant to create demand for new, expensive drugs,” Schweizer points out.

Here also is the brewing conflict with those who make money based on those ads — media companies that sell those ad spaces to Big Pharma. About 30 percent of the ads sold for any news show on TV are for pharmaceuticals. Many people have noticed how generally easy the news media at those networks go on pharmaceutical companies.

Keep reading